Blumchen, K.
Fischl, A.
Eiwegger, T.
Hamelmann, E.
Klimek, L.
Lange, L.
Szepfalusi, Z.
Vogelberg, C.
Beyer, K.
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 3 February 2022
Accepted: 10 March 2022
First Online: 26 April 2022
Conflict of interest
: K. Blumchen reports personal fees and/or grants and/or non-financial support from Aimmune Therapeutics, DBV Technologies, Thermofisher Scientific, Hipp GmbH, Novartis, Allergy therapeutics, HAL, ALK, Allergopharma, Nutricia, Nestlé, and Bausch and Lomb, outside the submitted work. A. Fischl reports personal fees from Aimmune Therapeutics and Synlab, outside the submitted work. T. Eiwegger reports personal fees from Danone/Nutricia/Milupa, Aimmune, ThermoFisher and EFSA, grants from DBV, personal fees and/or grant from ALK, non-financial support from Novartis, MADX, outside the submitted work. He is Co-PI or scientific lead in three investigator initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids and serves as an associate editor for <i>ALLERGY</i>. E. Hamelmann declares that he has no competing interests. L. Klimek has received funds for study implementation, consulting and/or expert work, lectures and/or training activities and/or paid work in a scientific advisory board from Aimmune, ALK-Abelló, Allergopharma, AstraZeneca, Bencard, Bionorica, Boehringer Ingelheim, Cytos, Circassia, HAL, GSK, Leti, Lofarma, Mylan, Novartis, Sanofi-Genzyme, Stallergenes and Roxall. L. Klimek is the current President of the Medical Association of German Allergologists, Vice President of the German Academy for Allergology and Environmental Medicine, Chairman of the ENT Section of the European Academy for Allergology and Clinical Immunology. He is editor of the <i>AllergoJournal</i> (Springer-Verlag). L. Lange reports personal fees as consultant for Aimmune, DBV Technologies and Nestlé. He reports personal fees for lectures for Aimmune, DBV Technologies, Nestlé and Nutricia. Z. Szepfalusi reports payments for advisory board activities with Aimmune. C. Vogelberg reports personal fees for Advisory Board Activities and Lectures from Aimmune Therapeutics and DBV Technology, outside the submitted work. K. Beyer reports grants and personal fees from Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma Mylan/Meda, Nestle, Novartis, ThermoFisher, Aimmune, Bencard and ALK, outside the submitted work.